Jazz Pharma Plc (JAZZ) 150.76 $JAZZ SHAREHOLDER ALERT:

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 8:20 PM

Jazz Pharma Plc (JAZZ) 150.76 $JAZZ

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"

(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz"

.
CPXX: 30.24 (+0.08), JAZZ: 150.76 (-5.26)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 9.55 (-0.18), JAZZ: 150.76 (-5.26), GRFS: 16.96 (-0.23), PBYI: 33.41 (-0.43)

Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company"

in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz"

. On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock.
CPXX: 30.24 (+0.08), JAZZ: 150.76 (-5.26)

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 150.76 (-5.26)

Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 150.76 (-5.26)

CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator"

(NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned.
CPXX: 30.24 (+0.08), JAZZ: 150.76 (-5.26)

Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.24 (+0.08), GXP: 30.03 (+0.03), WR: 56.37 (+0.26), MDT: 85.70 (-0.08), JAZZ: 150.76 (-5.26)

Shareholder Alert: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Celator Pharmaceuticals, Inc. - CPXX
PR Newswire - Tue May 31, 3:29PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Celator Pharmaceuticals Inc. ("Celator" or the "Company"

(NASDAQ: CPXX) (ISIN: US15089R1023) (CUSIP: 15089R102) concerning the proposed acquisition of Celator by Jazz Pharmaceuticals plc.
CPXX: 30.24 (+0.08), JAZZ: 150.76 (-5.26)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Celator Pharmaceuticals, Inc. to Jazz Pharmaceuticals plc - CPXX
ACCESSWIRE - Tue May 31, 11:22AM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
CPXX: 30.24 (+0.08), JAZZ: 150.76 (-5.26)

Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
PR Newswire Europe - Tue May 31, 2:30AM CDT
Transaction would add VYXEOS(TM), an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio
CPXX: 30.24 (+0.08), JAZZ: 150.76 (-5.26)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Jazz Pharmaceuticals plc
BusinessWire - Fri May 27, 1:47PM CDT
Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals" or the "Company"

(NASDAQ:JAZZ) concerning possible violations of federal securities laws.
JAZZ: 150.76 (-5.26)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jazz Pharmaceuticals plc - JAZZ
PR Newswire - Fri May 27, 10:41AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Jazz Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
JAZZ: 150.76 (-5.26)

Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
PR Newswire Europe - Wed May 18, 3:05PM CDT
Jazz Pharmaceuticals plc today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
JAZZ: 150.76 (-5.26)

Upgrade Alert for Jazz Pharmaceuticals (JAZZ)
Comtex SmarTrend(R) - Thu May 12, 3:39AM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $148.76 on volume of 1.9 million shares, above average daily volume of 718,000. Jazz Pharmaceuticals has overhead space with shares priced $148.76, or 18.1% below the average consensus analyst price target of $181.64. The stock should discover initial support at its 200-day moving average (MA) of $143.17 and subsequent support at its 50-day MA of $135.21.
JAZZ: 150.76 (-5.26)

Jazz Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 3.30%
Comtex SmarTrend(R) - Wed May 11, 12:23PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $149.61 to a high of $155.95. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $149.09 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JAZZ: 150.76 (-5.26)

Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 37.14 (-0.37), JAZZ: 150.76 (-5.26), ARQL: 1.78 (unch), APRI: 0.41 (-0.01)

Jazz Pharmaceuticals (JAZZ) Posts Q1 Earnings Beat, Updates 2016 Outlook
Madeleine Johnson - Zacks Investment Research - Tue May 10, 5:30PM CDT
Jazz Pharmaceuticals, Inc. (JAZZ) just released its first quarter fiscal 2016 earnings results, posting earnings of $1.87 per share and revenue of $336 million.
JAZZ: 150.76 (-5.26)

Jazz misses Street 1Q forecasts
Automated Insights - Tue May 10, 4:16PM CDT
DUBLIN (AP) _ Jazz Pharmaceuticals PLC (JAZZ) on Tuesday reported first-quarter profit of $74.1 million.
JAZZ: 150.76 (-5.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Durability Over Comfort: Vibram's Global Footwear Shift

Durability Takes Center Stage in Footwear Choices Out with the fleeting, in with the durable! Vibram, that powerhouse in performance soles known for its little yellow octagon logo, is grabbing durability by the laces and pushing it to the forefront of the footwear game. With a freshly minted global survey shaking things up, turns out almost 8 in 10 of us aren't just...

HONOR2U Celebrates Veterans' Transition to Public Safety

Veterans Day Reflections Beyond the Battlefield You can hang up the uniform, but you can't hang up the call of duty. This Veterans Day, HONOR2U salutes those stepping off the battlefield right into our communities—trading military fatigues for public safety gear. They've swapped one uniform for another, and it's not just about new fibers; it's about carrying the torch...

Hexnode XDR Expands Threat Detection, MacOS Support

Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...

Decoding Renters vs. Homeowners Insurance Needs

Breaking Down Policy Differences If you've ever scratched your head over the insurance landscape, join the club. Renters and homeowners insurance each serve a specific role on the financial protection battlefield, and knowing what you're signing up for is downright vital. Oscar Salas from HelloNation lays out the core differences for anyone wise enough to get their heads...

Azenta's 2026 Gains Mask Deeper Challenges Ahead

Azenta's Financial Tangle in Fiscal 2026 You ever feel those moments when the numbers paint a pretty picture, but your gut knows there's more beneath? That's Azenta, Inc. (Nasdaq: AZTA) for fiscal 2026. We’re gazing at a revenue uplift of 5% year over year, hitting $622 million from continuing operations. Great, right? But dig deeper, and the tale isn't all sunshine and...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Leech Tishman Bolsters Entertainment Group with Key Hires

In the legal world, adding a couple of seasoned litigation heavyweights to a practice is akin to fortifying your castle before a siege. Leech Tishman, a national law firm, has just done that by bringing Bryan M. Sullivan and Zachary C. Hansen aboard to bolster their Entertainment & Sports Industry Group. With these additions, they're not just shoring up their defenses;...

Call for Biotech Shift: Scarcity Drives Urgency

The Cry for an Industrial Biotech Shift Alright, folks, here's the deal: James Michael Matthew is waving a red flag. He's saying it's time to overhaul our approach to industrial biotechnology. Why? Because we're up against some big-time raw material shortages. Matthew's call isn't just a whisper in the wind; it's a siren echoing through an industry teetering on the edge...

Sound Credit Union, WTA Team Up for Trail Support

Heading Into the Great Outdoors with Every Swipe You ever feel like your money's going nowhere useful? Well, folks in Washington are about to flip the script thanks to Sound Credit Union and the Washington Trails Association (WTA). They've cooked up a slick new money move—a co-branded debit and credit card program—where every swipe backs the state's beloved trails. A...